CV-159 is a dihydropyridine derivative that acts as a Ca²⁺ antagonist and calmodulin inhibitor with anti-inflammatory effects; it significantly inhibits TNF-α-induced VCAM-1 expression in vascular smooth muscle cells (SMCs) in a concentration-dependent manner; suppresses TNF-induced reactive oxygen species (ROS) production; inhibits TNF-induced e-selectin expression; attenuates TNF-induced phosphorylation of JNK, p38, and NF-κB p65 (Ser536); provides significant protection against delayed neuronal death in the hippocampal CA1 region following transient forebrain ischemia in rats; reduces brain infarct size after permanent middle cerebral artery (MCA) occlusion; and significantly decreases MCA occlusion-induced edema (water content increase) in the infarcted cortex.